Solid dispersions of a ERB2 (HER2) inhibitor

US9457093B2 · kind B2 · utility

Assignee

• Array BioPharma, Inc. · US

Inventors

• David Shank Fry · Boulder, US
• Christopher M. Lindemann · Fort Collins, US
• Michael Preigh · Boulder, US
• Corey Bloom · Bend, US
• Christopher Donovan Craig · Bend, US
• Devon Brevard Dubose · Boulder, US
• Jeff Gautschi · Boulder, US
• Dan Smithey · Boulder, US

Key dates

• Filing date: Oct 12, 2012
• Grant date: Oct 4, 2016
• Expiry date: Oct 12, 2032

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P35/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A solid dispersion of N4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-N6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and processes for preparing the solid dispersion are provided herein. Also, a pharmaceutical composition comprising a solid dispersion of N4-(4-([1,2,4]triazolo[1,5-α]pyridin-7-yloxy)-3-methylphenyl)-N6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and uses thereof are provided herein.